Pramipexole versus selegiline in patients with Parkinson’s disease : an effectiveness and safety (EAS) analysis
المؤلفون المشاركون
Tao, Zhonghai
Chen, Jiechun
Xiao, Lijie
Liu, Chunfeng
المصدر
Iranian Red Crescent Medical Journal
العدد
المجلد 21، العدد 9 (30 سبتمبر/أيلول 2019)، ص ص. 1-8، 8ص.
الناشر
تاريخ النشر
2019-09-30
دولة النشر
الإمارات العربية المتحدة
عدد الصفحات
8
التخصصات الرئيسية
الموضوعات
الملخص EN
Background: Levodopa treatment is the gold standard in Parkinson’s disease but has the risk of dyskinesias.
Selegiline delays the introduction of levodopa and pramipexole is used as a symptomatic treatment in Parkinson’s disease.
Objectives: This study aimed to compare the effectiveness of pramipexole with selegiline in Parkinson’s disease patients.
Methods: Data regarding motor and cognitive impairments and plasma phospholipids of 500 Chinese patients with confirmed Parkinson’s disease from medical records of 1 January 2015 to 1 June 2016 were retrospectively evaluated.
Patients received either pramipexole (PP cohort, n = 250) or selegiline (SG cohort, n = 250).
Also, data regarding hospitalization, adverse effects, and expenditure were collected and analyzed from records of the follow-up period.
Results: After 3-years of treatments, selegiline and pramipexole both improved motor and cognitive impairments and decreased plasma phospholipid levels (P < 0.05 for all).
The intensity of improvement in motor and cognitive impairments and a decrease in the level of plasma phospholipids for pramipexole was higher than those of selegiline (P < 0.05 for all).
Pramipexole caused muscle weakness (P = 0.015) and peripheral edema (P = 0.0004).
While, selegiline caused cardiovascular disease (P = 0.008).
Higher numbers of patients in the SG cohort were hospitalized during 3-years of treatment than those in PP cohort (11 vs.
1, P = 0.009).
Selegiline treatment is more expensive than pramipexole (4,457 ± 345 ¥ vs.
3,649 ± 301 ¥/patient/year, P < 0.0001).
Conclusions: Pramipexole treatment may have better improvement in motor and cognitive impairments than selegiline with neuroprotective action and manageable side effects (Level of Evidence: III).
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Tao, Zhonghai& Chen, Jiechun& Xiao, Lijie& Liu, Chunfeng. 2019. Pramipexole versus selegiline in patients with Parkinson’s disease : an effectiveness and safety (EAS) analysis. Iranian Red Crescent Medical Journal،Vol. 21, no. 9, pp.1-8.
https://search.emarefa.net/detail/BIM-898285
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Tao, Zhonghai…[et al.]. Pramipexole versus selegiline in patients with Parkinson’s disease : an effectiveness and safety (EAS) analysis. Iranian Red Crescent Medical Journal Vol. 21, no. 9 (Sep. 2019), pp.1-8.
https://search.emarefa.net/detail/BIM-898285
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Tao, Zhonghai& Chen, Jiechun& Xiao, Lijie& Liu, Chunfeng. Pramipexole versus selegiline in patients with Parkinson’s disease : an effectiveness and safety (EAS) analysis. Iranian Red Crescent Medical Journal. 2019. Vol. 21, no. 9, pp.1-8.
https://search.emarefa.net/detail/BIM-898285
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 7-8
رقم السجل
BIM-898285
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر